Table 4.
References | Sample Size, Sex (% Women), and Average Age | Diagnostic Method | Comparison | Lipidomic Approach (Number of Lipid Molecules) |
Lipidomic Features |
---|---|---|---|---|---|
Seessle et al. (2020) [43] | (n = 74) 33% 50 years |
Elastography | Hereditary hemochromatosis (HH) vs. healthy | LC-MS (n.a.) |
|
Xu et al. (2020) [44] | (n = 34) 44% 41 years |
Biopsy | Polymorphisms of APOC3 | LC-MS (19) |
|
Sheridan et al. (2022) [48] | (n = 112) 28% 48 years |
H-MRS | HCV-G3 vs. HCV-G1 | LC-MS (n.a.) |
|
Van der Heijden et al. (2020) [51] | (n = 302) - % - years |
H-MRS | Levels of aldosterone and renin | NMR and LC-MS (231) |
|
Puri et al. (2009) [52] | (n = 125) - % - years |
Biopsy proven (NAFLD and NASH) * | NAFLD and NASH vs. healthy | TLC and GS-MS (266) |
|
Jurado-Fasoli et al. (2023) [54] | (n = 72) 54% 54 years |
Fatty liver index (blood biochemistry parameters) | Levels of n-6 FA, n-3 FA, and their derived oxylipins | LC-MS/MS (79) |
|
Imamura et al. (2017) [55] | (n = 27,296) - % - years |
ALT plasma levels | FA pattern score ([↑↑] of FA_18:2, FA_18:0, OC-FA, and VLC-SFA and [↓↓] of FA_18:3, FA_16:0, and LC-MUFA) | GS-MS (27) |
|
Mocciaro et al. (2023) [56] | (n = 109) 43% 55 years |
Biopsy * | NAFLD spectrum vs. controls | LC-MS (276) |
|
Ismail et al. (2020) [40] | (n = 53) 28% 44 years |
Biopsy | HCC and CLD vs. healthy | LC-MS (604) |
|
McGlinchey et al. (2022) [61] | (n = 627) 46% 52 years |
Biopsy | Steatosis vs. NASH vs. fibrosis | LC-MS and GC-MS (176) |
|
Mouskeftara (2024) [62] | (n = 37) 40% 54 years |
Elastography | NASH vs. healthy | LC-MS/MS (359) |
|
NAFLD vs. healthy and NAFLD vs. NASH | LC-MS/MS (359) |
|
|||
Velenosi et al. (2022) [63] | (n = 47) 51% 47 years |
Elastography and biopsy | Postprandial response in NAFLD vs. healthy | LC-MS and-MS/MS (3469) |
|
* NAFLD has been screened out in healthy volunteers by plasma biochemistry parameters. ↓: reduced; ↑: increased, [↑↑]: high concentrations; [↓↓]: low concentrations; n.a., not available.